PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology

NEW HAVEN, Conn., July 18, 2017 /PRNewswire/ -- PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")(TOKYO:4587) and Kleo Pharmaceuticals Inc., a New Haven-based company using its proprietary Antibody Recruiting Molecule ("ARM") and Synthetic Antibody Mimic ("SyAM") platform technologies to develop small molecule immunotherapies ("Kleo"), announced today a collaboration agreement to co-develop proprietary immune-oncology products in multiple indications.  

Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS") technology to identify macrocyclic/constrained peptides against multiple oncology targets of interest selected by Kleo, and to optimize hit peptides into optimized binders that will be engineered by Kleo into novel ARM and SyAM products. Kleo will receive an upfront payment and will have the right to develop and commercialize all compounds resulting from the collaboration. PeptiDream is eligible to receive a tiered share of proceeds from any products that arise from the collaboration based on degree to which PeptiDream funds development of the product. Specific financial terms were not disclosed.

"We are very excited to enter into this collaboration agreement with PeptiDream ," said Douglas Manion, MD, CEO of Kleo. "We think combining PeptiDream's PDPS technology with Kleo's ARM and SyAM platform represents a truly potent partnership that will generate many more effective targeted treatments for patients. We are looking forward to advancing this new paradigm of small molecule immunotherapies into the clinic."

"PeptiDream has long been on the forefront of transforming PDPS-identified peptides into peptide therapeutics, small molecule drugs, and peptide drug conjugates (PDCs)," said Keiichi Kubota, CEO of PeptiDream. "We greatly look forward to working with innovative leaders like Kleo to leverage our capabilities to develop the next generation of first-in-class and best-in-class immunotherapies."

About Kleo Pharmaceuticals Inc.  

Kleo Pharmaceuticals Inc. is a biotechnology company initially formed on the basis of intellectual property from the Spiegel Lab at Yale University and funded by a series A round led by Biohaven Pharmaceuticals Holding Ltd (NYSE: BHVN) . The company was founded by Dr. David Spiegel and Roy Prieb and is focused on developing a new class of targeted immunotherapies. The company is based in New Haven, CT. Further information regarding Kleo can be found at: http://kleopharmaceuticals.com.

About PeptiDream

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. Further information regarding PeptiDream can be found at: http://peptidream.com

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT INFORMATION

Contact:
Roy Prieb
Kleo Pharmaceuticals Inc.
203-691-6961
E: [email protected]
website: www.kleopharmaceuticals.com

SOURCE Kleo Pharmaceuticals Inc.

Related Links

http://kleopharmaceuticals.com